Score Your Stock

US stock · figures in US dollars · scored on full-year results

Pfizer Pfizer, Inc. Common Stock

PFE · Healthcare · Drug Manufacturers - General
Bottom 40% of scored stocks
OkayBottom 40% of scored stocks
Weak Spot

Pfizer scores 50/100 on fundamentals: in the bottom 40% of 503 scored S&P 500 stocks. Its strongest area is Risk (75/100); its weakest is Price Fairness (17/100). It carries 1 warning flag: Weak Spot.

Best
Risk 75
Weakest
Price 17
  • Carries a Weak Spot flag

An expensively priced stock, but price fairness needs attention.

What looks good
What to watch
Mkt capUS$ 174.0b#72 of 503 in the S&P 500EPSUS$ 0.76P/E40.1×✗ vs sector median 29.6×P/B2×✓ vs sector median 4×Div yield6%✓ Top 3% in the S&P 50052w range · 98% of range23.6230.67
as of 31 Oct 2026

Nearby peers

Ranks #38 of 60 in Healthcare by score

#1Universal Health Services79#36Thermo Fisher Scientific51#37Danaher50
#38Pfizer50
#39Vertex Pharmaceuticals50#40Align Technology48

One-Minute Summary

Why Pfizer scores 50

An expensively priced stock, but price fairness needs attention.

What looks good
What to watch

Business Strength

40
Why 40?
Pillar score: (0 + 1 + 2 + 1 + 0) = 4 of 10 points → 40
Return on Equity (ROE)5%Weak4-Year Revenue Growth+2%/yrOkay4-Year Profit Growth+27%/yrStrongNet Profit Margin7%OkayQuarterly Momentum-0%Weak
Show 3 charts

Net Profit & Equity, with ROE

Net Profit ↑ +104.5%Equity ↓ -4.3%ROE % 5.1%
Net ProfitEquityROE %
2.1b8.0b7.8b4.3b89.0b88.2b86.5b85.2b202320242025TTM2.4%9.1%9%5.1%

Revenue & Net Profit, with Net Margin

Revenue ↑ +7%Net Profit ↑ +104.5%Net Margin % 6.8%
RevenueNet ProfitNet Margin %
59.6b63.6b62.6b63.7b2.1b8.0b7.8b4.3b202320242025TTM3.6%12.6%12.4%6.8%

Sales have been roughly flat for 4 years: the business isn't really growing, just maintaining.

Profit climbed about 104.5% over 4 years: the business keeps more money as it grows.

Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)

Revenue ↓ -15.1%Net Profit ↓ -105.6%Net Margin % -1.6%
RevenueNet ProfitNet Margin %
17.7b17.8b13.7b14.7b16.7b17.6b14.4b15.0b4.5b410m3.0b2.9b3.5b-1.6b2.7b-248mQ3'24Q4'24Q1'25Q2'25Q3'25Q4'25Q1'26Q2'2625.2%2.3%21.6%19.9%21.3%-9.4%18.6%-1.6%
▲▲▬▲▼▼▼▼

Sales fell about 15.1% over the last 8 quarters: worth watching why.

The company made a loss in at least one of the last 8 quarters: the bars below zero are losses, not profits.

Why 50?
Pillar score: (1 + 1 + 1) = 3 of 6 points → 50
Debt-to-Equity0.7×OkayCurrent Ratio1.3×OkayInterest Coverage2.6×Okay
Show 2 charts

Debt vs Equity, with D/E ratio

Total Debt ↓ -10.8%Equity ↓ -4.3%D/E 0.7×
Total DebtEquityD/E
70.8b63.6b64.0b63.2b89.0b88.2b86.5b85.2b202320242025TTM0.8×0.7×0.7×0.7×

Borrowings fell about 10.8% over 4 years: the company is steadily getting safer.

Short-term assets vs bills, with Current Ratio

Current Assets ↓ -4.6%Current Liabilities ↓ -31.7%Current Ratio 1.3×
Current AssetsCurrent LiabilitiesCurrent Ratio
43.3b50.4b42.9b41.4b47.8b43.0b37.0b32.6b202320242025TTM0.9×1.2×1.2×1.3×
Why 63?
Pillar score: (1 + 2 + 2 + 0) = 5 of 8 points → 63
Dividend Quality6%Okay
Payout ratio: 226%
Operating Cash FlowPositive & growingStrongFree Cash FlowPositive & growingStrongCash & Cash EquivalentsShrinking & thinWeak
Show 3 charts

Operating vs Free Cash Flow

Operating CF ↑ +54%Free CF ↑ +129.2%
Operating CFFree CF
8.7b12.7b11.7b13.4b4.8b9.8b9.1b11.0b202320242025TTM

The business generates real cash, and more of it each year: a very healthy sign.

Cash vs Total Debt

Cash ↓ -65.8%Short-Term Debt ↓ -73.9%Total Debt ↓ -10.8%
CashShort-Term DebtTotal Debt
2.9b1.0b1.1b976m10.3b6.9b3.2b2.7b70.8b63.6b64.0b63.2b202320242025TTM

Dividends per Share, with Yield

DPS (cents) ↑ +7.5%Yield % 5.6%
DPS (cents)Yield %
4040404141424242434316016416817220222023202420254.1%5.5%7%5.6%

Dividends per share have been maintained or raised: management shares the rewards with you.

Why 17?
Pillar score: (0 + 0 + 1) = 1 of 6 points → 17
P/E Ratio40.1×WeakP/B Ratio2×WeakPEG Ratio1.5Okay
Show chart

Share Price: Weekly Closes (not part of the score)

US$ 30.52US$ 26.78US$ 23.04Oct '25Feb '26Jun '26Oct '26

The share price is up about 32.5% over the past year.

Why 75?
Pillar score: (1 + 2 + 2 + 2 + 2 + 0) = 9 of 12 points → 75
Earnings ConsistencyUnevenOkayDebt Trend (4yr)FallingStrongShare Count Trend (4yr)+0%/yrStrongInventory vs Sales (4yr)-3.1 pp/yr vs salesStrongAsset Turnover Trend (4yr)+20.4%StrongQuarterly ConsistencyLoss in 2 of 8 quartersWeak
Show chart

Revenue vs Inventory, with Inventory % of Revenue

Revenue ↑ +7%Inventory → -2.4%Inv. % of Rev. 15.6%
RevenueInventoryInv. % of Rev.
59.6b63.6b62.6b63.7b10.2b10.9b10.7b9.9b202320242025TTM17.1%17.1%17%15.6%
Ranks #38 of 60 in Healthcare by score

Sector peers

#1Universal Health Services79#36Thermo Fisher Scientific51#37Danaher50
#38Pfizer (you)50
#39Vertex Pharmaceuticals50#40Align Technology48

Full Financial History

Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.

Financial YearRevenueNet ProfitOperating Cash FlowFree Cash FlowCapExCashTotal DebtShort-Term DebtEquityCurrent AssetsCurrent LiabilitiesTotal AssetsTotal LiabilitiesInventoryDividendsReturn on Equity (ROE)Net Profit MarginDebt-to-EquityCurrent RatioInterest CoverageDividend Payout RatioDiv yieldP/E RatioP/B Ratio
2026US$ 63.7bUS$ 4.3bUS$ 13.4bUS$ 11.0bUS$ -2.4bUS$ 976.0mUS$ 63.2bUS$ 2.7bUS$ 85.2bUS$ 41.4bUS$ 32.6bUS$ 201.1bUS$ 115.6bUS$ 9.9b-5%7%0.7×1.3×2.6×226%---
2025US$ 62.6bUS$ 7.8bUS$ 11.7bUS$ 9.1bUS$ -2.6bUS$ 1.1bUS$ 64.0bUS$ 3.2bUS$ 86.5bUS$ 42.9bUS$ 37.0bUS$ 208.2bUS$ 121.4bUS$ 10.7bUS$ 172.0m9%12%0.7×1.2×3.8×126%7%17.5×1.6×
2024US$ 63.6bUS$ 8.0bUS$ 12.7bUS$ 9.8bUS$ -2.9bUS$ 1.0bUS$ 63.6bUS$ 6.9bUS$ 88.2bUS$ 50.4bUS$ 43.0bUS$ 213.4bUS$ 124.9bUS$ 10.9bUS$ 168.0m9%13%0.7×1.2×3.6×118%7%16.6×1.5×
2023US$ 59.6bUS$ 2.1bUS$ 8.7bUS$ 4.8bUS$ -3.9bUS$ 2.9bUS$ 70.8bUS$ 10.3bUS$ 89.0bUS$ 43.3bUS$ 47.8bUS$ 226.5bUS$ 137.2bUS$ 10.2bUS$ 164.0m2%4%0.8×0.9×1.5×436%7%64.1×1.5×